The MAPK1 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes carrying a targeted disruption of the MAPK1 gene. These polyclonal knockout cells provide a genetically heterogeneous loss-of-function model for studying ERK2-dependent signaling in a human B-cell context. The polyclonal format preserves the genetic diversity inherent to the edited cell pool, enabling robust functional studies without clonal selection pressures.
The Raji cell line, derived from an EBV-positive Burkitt lymphoma patient, is a well-established lymphoblastoid model with characteristic B-cell features, including surface immunoglobulin expression and the capacity for antigen presentation. As a suspension cell line, Raji cells retain key aspects of B-lymphocyte biology, such as active NF-??B and PI3K pathways, making them suitable for investigating oncogenic mechanisms in B-cell malignancies. The EBV-immortalized background further models virus-driven lymphomagenesis and provides a relevant platform for therapeutic intervention studies.
MAPK1 encodes ERK2, a central serine/threonine kinase in the RAS-RAF-MEK-ERK signaling cascade. Upon stimulation by growth factors such as EGF, FGF, and PDGF via receptor tyrosine kinases, RAS activates RAF kinases, which phosphorylate MEK1/2, leading to dual phosphorylation and activation of ERK2. Activated ERK2 translocates to the nucleus where it phosphorylates transcription factors including ELK1, c-FOS, and c-JUN, thereby regulating gene expression programs controlling cell proliferation, differentiation, and survival. ERK2 also modulates cytosolic and nuclear targets such as RSK, MYC, and ETS family members, and its activity is tightly controlled through interactions with scaffold proteins like KSR1, phosphatases like DUSP6, and regulatory adaptors such as PEA-15.
In Raji B lymphocytes, aberrant MAPK/ERK signaling is frequently implicated in Burkitt lymphoma pathogenesis and other non-Hodgkin lymphomas. Constitutive activation of this cascade can drive uncontrolled proliferation, impair apoptosis, and contribute to immune evasion. The MAPK1 knockout in Raji cells disrupts downstream ERK2-mediated transcriptional and cytoplasmic programs, allowing researchers to dissect the specific contributions of ERK2 to B-cell transformation, antigen receptor signaling, and cytokine responsiveness. This model is particularly valuable for exploring synthetic lethal interactions and adaptive feedback mechanisms that arise upon ERK2 loss in lymphoid malignancies.
Researchers can use these polyclonal knockout cells to investigate MAPK/ERK signaling in lymphomagenesis, B-cell differentiation, and drug resistance. Representative assays include Western blotting for total and phospho-ERK2, phospho-signaling flow cytometry, proliferation and apoptosis assays, and drug sensitivity screens with MEK inhibitors. Co-immunoprecipitation and RNA-seq analyses further enable the study of ERK2 interactomes and transcriptomic changes. For further technical information, please contact Ascent Research.
